Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Nuvation Bio Inc.NYSE: NUVB
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income remains negative
Q2 FY2026 operating income was -$51.04M, compared with -$63.59M a year earlier. Trailing-twelve-month operating income was -$137.63M.
Context
- Operating income amounted to 338.7% of revenue in FY2025, down 7188.6 pp from a year earlier.
- Operating income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 10 analysts of -$129.29M (+39.3%) for the fiscal year ending Dec 2026, a slowdown from the +64.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$51.04M-1415.0% QoQ
- Last fiscal yearDec 2025
- -$213.06M+64.0% YoY
- LTMJun 2026
- -$137.63M+38.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.7% | +33.7% | +13.9 pp |
| 1 year | +64.0% | +39.3% | -24.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (213.06M) USD
- Year-over-year change
- +64.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (213.06M) | +64.0% |
| FY2024 | 2024-12-31 | (592.63M) | -493.7% |
| FY2023 | 2023-12-31 | (99.82M) | +16.6% |
| FY2022 | 2022-12-31 | (119.73M) | -28.3% |
| FY2021 | 2021-12-31 | (93.32M) | — |
Operating Income vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 operating income of -$137.63M is the 2nd highest of the 11 companies compared; the peer median is -$238.13M.
- Its year-over-year change of +38.7% is the 2nd highest of 11, against a peer median of -19.0%.
- Operating income amounts to 81.0% of revenue for NUVB, versus a peer median of 575.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $150.75M | +189.8% | — | 48.4% | |
| LTM Jun 2026 | -$137.63M | +38.7% | — | 81.0% | |
| LTM Mar 2026 | -$156.98M | -38.2% | — | 726.3% | |
| LTM Mar 2026 | -$191.33M | -12.9% | — | 1057.5% | |
| LTM Sep 2026 | -$202.19M | +22.6% | — | 298.0% | |
| LTM Sep 2026 | -$218.18M | -20.6% | — | — | |
| LTM Jun 2026 | -$258.07M | -17.5% | — | — | |
| LTM Mar 2026 | -$299.44M | -46.7% | — | 575.4% | |
| LTM Sep 2026 | -$334.5M | -30.5% | — | 298657.1% | |
| LTM Jun 2026 | -$405.2M | -9.0% | — | 569.7% | |
| LTM Jun 2026 | -$415.76M | -76.1% | — | — | |
| Peer median (excluding NUVB) | -$238.13M | -19.0% | — | 575.4% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.